Product Information

recomBlot CMV IgG   CB33/5502

recomBlot CMV IgM   CB33/5503

 

RecomBlot

Qualitative in vitro test for the indirect detection and safe identification of pathogen specific antibodies. As a western blot the recomBlot serves to confirm the results from screening assays such as enzyme immuno assays (ELISA) or immunofluorescence assays (IFA). In contrast to ordinary immunoblot assays, the antigens are presented optimal in the recomBlot without disturbing and cross-reacting proteins. For this reason the recomBlot displays a high specificity and sensitivity. Furthermore the recomBlot is easy and secure to read

 

Immunoblot test with antigens produced by recombinant techniques for the detection of IgG or IgM antibodies directed against Cytomegalovirus (CMV).

 

Human Cytomegalovirus (CMV) belongs to the family of herpes viruses. Infections are common worldwide. The virus persists during the whole life of the infected patient and transmission can result from contact with infected secretions or direct contact with mucous membranes, through sexual contacts, from mother to the unborn child and through blood transfusions and transplantations.

 

Most acquired CMV infections are often asymptomatic. Clinical pictures vary strong and depend on the age and the immune status. CMV infections of immune competent people occur in most cases asymptomatic or only with minor symptoms. Immuncompromised patients (during transplantations, HIV-infections, chemotherapy) are often (deadly) infected with CMV.

 

Primary infections during pregnancy can, in 40% of all cases, lead to prenatal infections and infected premature babies who suffer in 10% of all cases under heavy damages. A virus, acquired during pregnancy, can also be transmitted vertically. The clinical consequences on the other hand are more moderate and the prognosis is good.

 

The recomBlot CMV is a western blot assay for the confirmation of uncertain and positive screening results. This assay method allows the proof and identification of IgG and IgM antibodies against different antigen groups. By using recombinant DNA technology highly specific and characteristic proteins can be used. The determination of different antibodies and the possibility of an additional avidity testing is providing additional information for the differentiation between a primary infection and a reactivation.